Instil Bio, Inc. Stock-Based Compensation
Instil Bio, Inc. (TIL) reported Stock-Based Compensation of $2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Instil Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.04M, a 43.20% decline year-over-year.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $985.00K, a 71.82% decline year-over-year.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.61M, a 64.32% decline year-over-year.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.77M, a 56.54% decline year-over-year.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $8.69M, a 49.63% decline from fiscal 2024.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $17.26M, a 5.00% decline from fiscal 2023.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $18.17M, a 40.32% decline from fiscal 2022.
- Instil Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $30.44M, a 16.20% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.02M 10-Q · filed 2026-08-13 | $3.63M derived: sum of 3 quarters · filed 2026-08-13 | $5.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $985.00K 10-Q · filed 2026-05-15 | $2.59M derived: sum of 2 quarters · filed 2026-05-15 | $4.36M derived: sum of 3 quarters · filed 2026-05-15 | $6.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.37M derived: sum of 2 quarters · filed 2026-03-27 | $5.20M derived: sum of 3 quarters · filed 2026-08-13 | $8.69M 10-K · filed 2026-03-27 |
| 2025-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.59M derived: sum of 2 quarters · filed 2026-08-13 | $7.09M 10-Q · filed 2025-11-13 | $11.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.32M 10-Q · filed 2026-08-13 | $9.82M derived: sum of 3 quarters · filed 2026-08-13 | $13.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.50M 10-Q · filed 2026-05-15 | $8.00M derived: sum of 2 quarters · filed 2026-05-15 | $12.06M derived: sum of 3 quarters · filed 2026-05-15 | $16.24M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $8.57M derived: sum of 2 quarters · filed 2026-03-27 | $12.74M derived: sum of 3 quarters · filed 2026-03-27 | $17.26M 10-K · filed 2026-03-27 |
| 2024-09-30 | $4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $8.24M derived: sum of 2 quarters · filed 2025-11-13 | $12.76M 10-Q · filed 2025-11-13 | $17.31M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $8.69M 10-Q · filed 2025-08-13 | $13.24M derived: sum of 3 quarters · filed 2025-08-13 | $17.91M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $4.51M 10-Q · filed 2025-05-13 | $9.07M derived: sum of 2 quarters · filed 2025-05-13 | $13.74M derived: sum of 3 quarters · filed 2025-05-13 | $18.15M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $9.22M derived: sum of 2 quarters · filed 2025-03-04 | $13.64M derived: sum of 3 quarters · filed 2025-03-04 | $18.17M 10-K · filed 2025-03-04 |
| 2023-09-30 | $4.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $9.08M derived: sum of 2 quarters · filed 2024-11-13 | $13.61M 10-Q · filed 2024-11-13 | $20.26M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $8.94M 10-Q · filed 2024-08-13 | $15.59M derived: sum of 3 quarters · filed 2024-08-13 | $23.57M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.53M 10-Q · filed 2024-05-10 | $11.17M derived: sum of 2 quarters · filed 2024-05-10 | $19.16M derived: sum of 3 quarters · filed 2024-05-10 | $27.48M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $14.63M derived: sum of 2 quarters · filed 2024-03-21 | $22.95M derived: sum of 3 quarters · filed 2024-03-21 | $30.44M 10-K · filed 2024-03-21 |
| 2022-09-30 | $7.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $16.30M derived: sum of 2 quarters · filed 2023-11-13 | $23.80M 10-Q · filed 2023-11-13 | $32.70M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $15.82M 10-Q · filed 2023-08-14 | $24.72M derived: sum of 3 quarters · filed 2023-08-14 | $33.46M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $7.49M 10-Q · filed 2023-05-11 | $16.40M derived: sum of 2 quarters · filed 2023-05-11 | $25.13M derived: sum of 3 quarters · filed 2023-05-11 | $30.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $17.64M derived: sum of 2 quarters · filed 2023-03-31 | $23.39M derived: sum of 3 quarters · filed 2023-03-31 | $26.20M 10-K · filed 2023-03-31 |
| 2021-09-30 | $8.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $14.48M derived: sum of 2 quarters · filed 2022-11-14 | $17.29M 10-Q · filed 2022-11-14 | $17.71M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $8.56M 10-Q · filed 2022-08-12 | $8.97M derived: sum of 3 quarters · filed 2022-08-12 | $9.30M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.81M 10-Q · filed 2022-05-16 | $3.23M derived: sum of 2 quarters · filed 2022-05-16 | $3.56M derived: sum of 3 quarters · filed 2022-05-16 | $4.46M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $745.00K derived: sum of 2 quarters · filed 2022-03-07 | $1.64M derived: sum of 3 quarters · filed 2022-03-07 | $1.71M 10-K · filed 2022-03-07 |
| 2020-09-30 | $330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.23M derived: sum of 2 quarters · filed 2021-11-15 | $1.29M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $899.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $961.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $62.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |